key: cord-0821254-pskeghiy authors: Cirillo, Nicola title: Reported orofacial adverse effects of COVID‐19 vaccines: The knowns and the unknowns date: 2021-02-19 journal: J Oral Pathol Med DOI: 10.1111/jop.13165 sha: 238a0c4d1fed743a9123a6b886d3370b9d43a757 doc_id: 821254 cord_uid: pskeghiy INTRODUCTION: Adverse events associated with vaccine administration can manifest in the oral cavity and orofacial region. Hence, the aim of this study was to compare the orofacial adverse effects of two recently authorised COVID‐19 vaccines, namely BNT162b2 and mRNA‐1273. METHODS: Publicly available data on BNT162b2 and mRNA‐1273 vaccines were accessed from the relevant regulatory authorities in the United States, Canada, European Union and United Kingdom. Both patient/recipient information and healthcare professional fact sheets for each of these drugs were manually searched to find their orofacial adverse effects. RESULTS: Adverse events affecting the orofacial region were reported for both vaccines. These were rare and included acute peripheral facial paralysis (Bell's palsy), facial swelling, and swelling of the lips, face or tongue associated with anaphylaxis. There was heterogeneity in the acknowledgement of vaccine‐related adverse events in North America compared with Europe. CONCLUSION: Globally, there are inconsistencies in the description of adverse effects presenting in the orofacial region of the COVID‐19 vaccines BNT162b2 and mRNA‐1273. We believe that awareness of these orofacial manifestations will improve recognition, management and reporting of vaccine‐related adverse effects. safe vaccines against this virus has been extremely fast. 3 Of the many candidates, currently two RNA-based COVID-19 vaccines have been granted emergency use and marketing authorisation by the relevant regulatory agencies in North America and Europe and are being used worldwide. A third vaccine (AZD1222, Oxford-AstraZeneca) has currently been approved for use in the UK. Initial efficacy and safety data for both BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines have been published 4, 5 and product monographs including relevant information from the trials are available. As vaccination campaigns kick off worldwide, and with several billion doses predicted to be administered in the near future, 6 it is likely that a sizeable number of adverse events will be observed. Hence, the aim of this study was to research and compare the reported orofacial adverse effects of two COVID-19 vaccines. Dentists' knowledge of these orofacial manifestations will improve recognition, management and reporting of vaccine-related adverse effects. Table S1 . Reported side/adverse/undesirable effects concerning the orofacial region were extracted and tabulated. Information leaflets intended for use of non-healthcare professionals were referred to as Fact sheet for the recipients and caregivers (US), Patient Medication Information (Canada), Information for the user (EU) and Information for UK recipients (UK). Product Information for healthcare professionals was identified as Fact sheet for vaccination providers (US), Health Professional Information (Canada), Summary of product characteristics (EU) and Information for Healthcare Professionals (UK) (Table S1). Both vaccines were associated with potential orofacial adverse effects. Rare (up to 1 in 1000 people) but serious allergic reactions causing swelling of the face, lips or tongue were reported (Tables 1 and 2 ). Description of localised orofacial adverse effects including facial drooping (Bell's palsy) was found, however these were not disclosed in the information for patients in US and Canada ( Table 1) . Swelling of the face in patients who have had facial cosmetic injections occurred exclusively with the mRNA-1273 vaccine but was only reported in the product information available in EU and UK. For EU and UK consumers, temporary one sided facial drooping/ acute peripheral facial paralysis (Bell's palsy) and facial swelling were reported in the product information to both patients (Table 1) and healthcare professionals (Table 2) . Conversely, US and Canada vaccine fact sheets for patients did not report these side effects. Bell's palsy was also not acknowledged in the Health Professional Information of Canada. swelling of the lips, face or tongue associated with anaphylaxis. There appear to be inconsistencies in the description of these effects in the information provided to patients and healthcare profes- In general, we found that description of ADRs was more difficult to find in the US versions of product information sheets. Conversely, information for healthcare professionals in Europe and the UK reported a tabulated list of adverse reactions and their frequency, and were classified according to MedDRA system organ class. Unlike previous studies, 9 we assessed orofacial drug-related adverse effects as reported both in the registered drug company full product information/monograph as well as in the package leaflet containing patient/consumer information. We believe that this is a more comprehensive approach and, in agreement with this view, our study found that some information was not explicitly disclosed to users. It is to note that diseases were included in our list only when the orofacial manifestations were explicitly stated, therefore, it is likely that the occurrence of oral ADRs was underreported. For example, common ADRs such as muscle pain, joint pain and enlarged lymph nodes may have manifested in the head and neck region and hence were not captured in the available reports. In conclusion, we found that both BNT162b2 and mRNA-1273 COVID-19 vaccines are associated with orofacial ADRs and that there is heterogeneity in the description of these adverse effects worldwide. The author declares no conflicts of interest. Nicola Cirillo, conceptualization; data curation; formal analysis; investigation; methodology; writing-original draft. The peer review history for this article is available at https://publo TA B L E 2 List of orofacial adverse effects of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines as reported in the information to healthcare providers a Developing covid-19 vaccines at pandemic speed COVID-19 vaccine: a comprehensive status report C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum Medicines and Healthcare products Regulatory Agency. Information for Healthcare Professionals on COVID-19 Vaccine Moderna Oral adverse effects of drugs: taste disorders